{
    "nctId": "NCT00379197",
    "briefTitle": "Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer",
    "officialTitle": "Phase II Study of Naltrexone for the Treatment of Hormone-Refractory, Metastatic Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 13,
    "primaryOutcomeMeasure": "Disease Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Metastatic, hormone-receptor positive breast cancer\n* Disease that has progressed despite previous systemic hormonal therapy. Hormone therapy must be terminated at least 2 weeks prior to study enrollment.\n* Prior chemotherapy, immunotherapy, or biological therapy is allowed if at least 3 weeks since last treatment. Patient must recover from the acute toxic effects of the treatment prior to study enrollment.\n* Measurable disease as defined by solid tumor response (RECIST) criteria or non-measurable bone disease that is Positron-emission tomography (PET) avid\n* Karnofsky performance status \\>70%\n* Female, age 18 years or older\n* Adequate organ function within 14 days of study enrollment including the following:\n\n  * Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) \u2265 1.5 x 10\\^9/L, platelets \\>75 x 10\\^9/L, and hemoglobin \\> 8 g/dL\n  * Hepatic: bilirubin \u2264 2 times the upper limit of normal (\u00d7 ULN), aspartate transaminase (AST) and alanine transaminase (ALT) \u2264 2 \u00d7 ULN. (AST and ALT \u2264 5 \u00d7 ULN is acceptable if liver has tumor involvement)\n  * Renal: creatinine \u2264 2 times the upper limit of normal\n* Women of childbearing potential are required to use an effective method of contraception (ie, a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) during the study and for 3 months after the last dose of study drug.\n* Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.\n\nExclusion criteria:\n\n* Brain metastases unless stable for 1 month or more following radiation therapy.\n* Pregnant or lactating women. PET-CT is not approved during pregnancy. A negative urine or serum pregnancy test is required for all females of child bearing potential within 7 days prior to study entry. Pregnancy testing is not required for post-menopausal or surgically sterilized women.\n* Use of any short-acting or long-acting opioid medication (including morphine, meperidine, oxycodone, hydromorphone, hydrocodone, fentanyl, tramadol) within 10 days prior to study enrollment\n* Pain uncontrolled with the use of non-narcotic drugs (acetaminophen or non-steroidal medications)\n* History of sensitivity to naltrexone\n* Acute hepatitis or liver failure\n* Immunosuppressive therapy for patients with autoimmune diseases, organ transplant, or other indications",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}